MFA-370 / Ectin Research - LARVOL DELTA

MANHATTAN: A Study of MFA-370 in Patients with Metastatic Urothelial Cancer (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Ectin Research AB | N=50 ➔ 0 | Trial completion date: Dec 2024 ➔ Dec 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Dec 2024 ➔ Dec 2025

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial withdrawal • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Efficacy studies in an animal model for uveal melanoma show inhibited tumor growth [Google translation] (Cision) - "Ectin Research AB...announces today that preclinical studies of MFA-370 in zebrafish model for the aggressive eye cancer uveal melanoma suggests that MFA-370 results in reduced tumor growth...The company has based on previously identified appropriate doses of MFA-370 now started the effect studies in zebrafish embryos. Preliminary preclinical data suggest that uveal melanoma tumor cells treated with the combination therapy MFA-370 are inhibited in their growth in significantly greater extent than when treated with each substance separately....'The new results can be used to link experts in uveal melanoma to us for further planning product development of MFA-370 ahead of clinical studies.'"

Preclinical • Eye Cancer • Oncology • Solid Tumor • Uveal Melanoma

MFA-370 induces unique gene expression pattern when regulating tumour cell growth (Ectin Research Press Release) - "Ectin Research AB...has announced that the company has performed gene expression analysis, demonstrating that the combination treatment MFA-370 has unique and widespread effects on genes involved in the regulation of tumour growth...in collaboration with the preclinical Contract Research Organization (CRO) generated gene expression analysis data from stimulations of MFA-370 on three different cancer cell models (bladder cancer, triple-negative breast cancer, and uveal melanoma) and demonstrated that MFA-370 gives rise to unique and widespread effects on genes associated with the regulation of tumour progression. The effect on the gene expression pattern is considerably more significant for the combination treatment MFA-370 than for the individual substances themselves....The investigation is still ongoing and aims to identify MFA-370’s potential role in modulating the tumour microenvironment and how it may potentially affect different kinds of immune..."

Preclinical • Bladder Cancer • Breast Cancer • Eye Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • Uveal Melanoma

Ectin establishes zebrafish models for uveal melanoma (Ectin Research Press Release) - "Ectin Research AB...has today (April 8th 2024) announced that during the beginning of 2024, the company has set up models in zebrafish to study how MFA-370 affects tumor development in the aggressive eye cancer uveal melanoma....In collaboration with a preclinical CRO (Contract Research Organization), Ectin has successfully set up and validated model systems to study uveal melanoma in zebrafish embryos. In parallel with the development of translatable animal models for uveal melanoma, Ectin has studied how MFA-370 is tolerated by zebrafish embryos. These studies have now been completed and the next step is to carry out efficacy studies in one of the now-established disease models....'We look forward to being able to present preclinical efficacy data from the zebrafish studies in 2024.'"

Licensing / partnership • Preclinical • Eye Cancer • Oncology • Solid Tumor • Uveal Melanoma

Ectin Research AB strengthens and expands its preclinical portfolio with additional areas of application for MFA-370. [Google translation] (Cision) - "Ectin Research AB...announces today that the Company's preclinical investment through commissioned research has both strengthened and expanded the Company's indication areas for MFA-370. The aim was to investigate in various experimental models whether Ectin's combination therapy MFA-370 could be used in the treatment of additional cancer indications. The new preclinical studies strengthen previous research for the treatment of metastatic urothelial bladder cancer (mUBC) with MFA-370 as well as suggest that triple negative breast cancer (TNBC) and the rare disease uveal melanoma (UM) could also be treated with MFA-370....preclinical studies have been carried out on cancer cells isolated from a patient with urothelial bladder cancer, organoids, where the Company could clearly discern an antiproliferative effect of MFA-370 treatment on the cancer cells."

Preclinical • Bladder Cancer • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • Uveal Melanoma

Preclinical studies of Ectin Research AB's MFA-370 indicate both inhibited tumor growth and a tumor-shrinking effect in an animal model for triple-negative breast cancer. [Google translation] (Cision) - "Ectin Research AB...announces today that the Company's preclinical investment through commissioned research indicates that the combination therapy MFA-370 has both a growth-inhibiting and tumor-shrinking effect on triple-negative breast cancer tumors in animals. The new preclinical studies in an animal model support the company's previous positive preclinical research results of cultured triple-negative breast cancer cells treated with MFA-370....The results from the animal studies thus support previous preclinical studies of MFA-370. The dosage of MFA-370 used in treating the animals will further contribute valuable information to the Company's clinical program."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Ectin Research AB (publ) publishes half-yearly report for the period January 1, 2023 - June 30, 2023 [Google translation] (Cision) - "Ectin focuses on financing the company's operations to create the conditions for our planned phase I/II clinical trial with MFA-370 for patients with metastatic urothelial bladder cancer. With existing capital, we are also working further on preclinically developing MFA-370 and potentially expanding the product portfolio, as well as planning the company's development work within Clinical Manufacturing and Control (CMC) and formulation of MFA-370."

Financing • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer